Literature DB >> 1904879

Measurement of cerebral monoamine oxidase B activity using L-[11C]deprenyl and dynamic positron emission tomography.

A A Lammertsma1, C J Bench, G W Price, J E Cremer, S K Luthra, D Turton, N D Wood, R S Frackowiak.   

Abstract

A tracer kinetic procedure was developed for the measurement of monoamine oxidase type B (MAO-B) activity using L-[11C]deprenyl and positron emission tomography (PET). The kinetic model consisted of two tissue compartments with irreversible binding to the second compartment (three rate constants). In addition, a blood volume component was included. Special attention was given to the accurate measurement of the plasma and whole blood input functions. The method was applied to the measurement of the dose-response curve of a reversible MAO-B inhibitor (Ro 19-6327). From the results, it followed that the rate constant for irreversible binding (k3) appeared to be a better index of MAO-B activity than the net influx constant Ki. Furthermore, regional analysis demonstrated that Ki, but not k3, was flow dependent. This implies that full kinetic analysis is required for an accurate assessment of MAO-B activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904879     DOI: 10.1038/jcbfm.1991.103

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  16 in total

Review 1.  Determination of the Input Function at the Entry of the Tissue of Interest and Its Impact on PET Kinetic Modeling Parameters.

Authors:  M'hamed Bentourkia
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 2.  Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling approaches.

Authors:  Matteo Tonietto; Gaia Rizzo; Mattia Veronese; Masahiro Fujita; Sami S Zoghbi; Paolo Zanotti-Fregonara; Alessandra Bertoldo
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-14       Impact factor: 6.200

Review 3.  Modeling of PET data in CNS drug discovery and development.

Authors:  Katarina Varnäs; Andrea Varrone; Lars Farde
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-05-10       Impact factor: 2.745

4.  Synthesis and in vivo studies of a specific monoamine oxidase B inhibitor: 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)- 1,3,4-oxadiazol-[11C]-2(3H)-one.

Authors:  S Bernard; C Fuseau; L Schmid; R Milcent; C Crouzel
Journal:  Eur J Nucl Med       Date:  1996-02

5.  Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography.

Authors:  G Paternostro; P G Camici; A A Lammerstma; N Marinho; R R Baliga; J S Kooner; G K Radda; E Ferrannini
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

6.  Effect of tissue heterogeneity on quantification in positron emission tomography.

Authors:  G Blomqvist; A A Lammertsma; B Mazoyer; K Wienhard
Journal:  Eur J Nucl Med       Date:  1995-07

Review 7.  Imaging the head: functional imaging.

Authors:  G V Sawle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

8.  Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET.

Authors:  Pablo Rusjan; Pamela Sabioni; Patricia Di Ciano; Esmaeil Mansouri; Isabelle Boileau; Alexia Laveillé; Marc Capet; Thierry Duvauchelle; Jean-Charles Schwartz; Philippe Robert; Bernard Le Foll
Journal:  Br J Pharmacol       Date:  2020-05-23       Impact factor: 8.739

9.  In vivo quantification of monoamine oxidase A in baboon brain: a PET study using [(11)C]befloxatone and the multi-injection approach.

Authors:  Michel Bottlaender; Héric Valette; Jacques Delforge; Wadad Saba; Ilonka Guenther; Olivier Curet; Pascal George; Frédéric Dollé; Marie-Claude Grégoire
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-18       Impact factor: 6.200

Review 10.  Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.

Authors:  Jan Booij; Paul Kemp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-30       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.